Skip to main content

Advertisement

Table 2 Results of prospective randomized trials

From: Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit

Country Author Ref Trial name Year Conclusions
Use in respiratory infections
Switzerland Christ-Crain [20] None 2006 PCT level prevented initial antibx use, earlier discontinuation antibx, less overall use
Switzerland Briel [23] None 2008 PCT level prevented initial antibx use, decreased overall antibx exposure and duration
Swiss/USA Stolz [25] None 2009 PCT level allowed earlier discontinuation antibx, decreased total exposure and duration
Switzerland Schuetz [26] ProHosp 2009 adverse outcomes similar, PCT group had fewer adverse events, less total antibx use
Use in sepsis
Switzerland Nobre [21] None 2008 PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure
Germany Schroeder [22] None 2008 PCT allowed earlier discontinuation of antibx, cost of antibx reduced
Use in sepsis in the ICU setting
Germany Hochreiter [24] None 2009 PCT allowed earlier discontinuation of antibx, shorter ICU length of stay
France Bouadma [27] PRORATA 2010 PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure
Netherlands De Jong [28] SAPS 2013 No longer recruiting patients, results pending
Australia Shehabi [30] ProGuard 2014 PCT group had 2 less days of antibx but not statistically significant
  1. Ref references, PCT procalcitonin, antibx antibiotics